Building research infrastructure to advance precision medicine in colorectal cancer.

IF 3.4 Q2 ONCOLOGY JNCI Cancer Spectrum Pub Date : 2025-03-20 DOI:10.1093/jncics/pkaf027

Stephanie L Schmit, Nicole C Loroña, Daniel Sobieski, Marco Matejcic, Nathalie T Nguyen, Hannah J Hoehn, Diana B Diaz, Kritika Shankar, Eric M Cockman, Esther Jean-Baptiste, Ya-Yu Tsai, R Blake Buchalter, Karina Brito, Rusche Wilson, Domenico Coppola, Clifton Fulmer, Ozlen Saglam, Alexandra F Tassielli, Francisca Beato, Ruifan Dai, Jennifer A Freedman, Kristen Purrington, Bo Hu, Daniel Mcgrail, Heather Gibson, Kun Jiang, Teresita Muñoz-Antonia, Idhaliz Flores, Edna Gordian, José A Oliveras Torres, Iona Cheng, Erin L Van Blarigan, Seth I Felder, Julian A Sanchez, Jason B Fleming, Erin M Siegel, Douglas Cress, Patricia Thompson, Mariana C Stern, Jamie K Teer, Jane C Figueiredo

{"title":"Building research infrastructure to advance precision medicine in colorectal cancer.","authors":"Stephanie L Schmit, Nicole C Loroña, Daniel Sobieski, Marco Matejcic, Nathalie T Nguyen, Hannah J Hoehn, Diana B Diaz, Kritika Shankar, Eric M Cockman, Esther Jean-Baptiste, Ya-Yu Tsai, R Blake Buchalter, Karina Brito, Rusche Wilson, Domenico Coppola, Clifton Fulmer, Ozlen Saglam, Alexandra F Tassielli, Francisca Beato, Ruifan Dai, Jennifer A Freedman, Kristen Purrington, Bo Hu, Daniel Mcgrail, Heather Gibson, Kun Jiang, Teresita Muñoz-Antonia, Idhaliz Flores, Edna Gordian, José A Oliveras Torres, Iona Cheng, Erin L Van Blarigan, Seth I Felder, Julian A Sanchez, Jason B Fleming, Erin M Siegel, Douglas Cress, Patricia Thompson, Mariana C Stern, Jamie K Teer, Jane C Figueiredo","doi":"10.1093/jncics/pkaf027","DOIUrl":null,"url":null,"abstract":"Background: Addressing critical gaps in precision medicine initiatives in colorectal cancer (CRC) requires building larger collaborative studies.Methods: The Latino Colorectal Cancer Consortium (LC3) is a resource that harmonizes data collected in observational studies with data from individuals who identify as Hispanic/Latino with a diagnosis of primary colorectal adenocarcinoma. Data collected includes demographics, medical history, family history, and lifestyle risk factors from patient-completed surveys. Vital status, cause of death, treatment, and clinicopathological characteristics were obtained through medical chart abstraction, pathology reports and/or linkage to state cancer registries. Blood, saliva, or normal colonic tissues were used to extract and genotype germline DNA. Tumor tissue (snap frozen or formalin-fixed paraffin-embedded) were evaluated by pathologists for diagnosis, tissue content, tumor cellularity, necrosis, immune infiltration, and additional histopathologic characteristics. A centralized database with a virtual tumor repository was created to facilitate collaborative research.Results: As of April 2024, LC3 assembled data from 2,210 patients (diagnosed 1994 to 2023). The mean age at diagnosis was 57 (range: 19-93) years; 54.3% of participants were male, and 62.0% had been diagnosed with colon cancer. Surveys were completed by 1,722 (77.8%) participants. Ongoing multi-omics profiling on up to 600 patients include: genome-wide germline genotyping, paired tumor/normal whole exome sequencing, bulk RNA-seq, T cell receptor immunosequencing, and multiplex immunofluorescence.Conclusions: This consortium fills an important gap in research infrastructure in CRC as well as improving precision medicine initiatives for all individuals.","PeriodicalId":14681,"journal":{"name":"JNCI Cancer Spectrum","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JNCI Cancer Spectrum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/jncics/pkaf027","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Addressing critical gaps in precision medicine initiatives in colorectal cancer (CRC) requires building larger collaborative studies.

Methods: The Latino Colorectal Cancer Consortium (LC3) is a resource that harmonizes data collected in observational studies with data from individuals who identify as Hispanic/Latino with a diagnosis of primary colorectal adenocarcinoma. Data collected includes demographics, medical history, family history, and lifestyle risk factors from patient-completed surveys. Vital status, cause of death, treatment, and clinicopathological characteristics were obtained through medical chart abstraction, pathology reports and/or linkage to state cancer registries. Blood, saliva, or normal colonic tissues were used to extract and genotype germline DNA. Tumor tissue (snap frozen or formalin-fixed paraffin-embedded) were evaluated by pathologists for diagnosis, tissue content, tumor cellularity, necrosis, immune infiltration, and additional histopathologic characteristics. A centralized database with a virtual tumor repository was created to facilitate collaborative research.

Results: As of April 2024, LC3 assembled data from 2,210 patients (diagnosed 1994 to 2023). The mean age at diagnosis was 57 (range: 19-93) years; 54.3% of participants were male, and 62.0% had been diagnosed with colon cancer. Surveys were completed by 1,722 (77.8%) participants. Ongoing multi-omics profiling on up to 600 patients include: genome-wide germline genotyping, paired tumor/normal whole exome sequencing, bulk RNA-seq, T cell receptor immunosequencing, and multiplex immunofluorescence.

Conclusions: This consortium fills an important gap in research infrastructure in CRC as well as improving precision medicine initiatives for all individuals.

查看原文